MSD Pharmaceuticals, the wholly-owned subsidiary of global leader Merck, has entered into the cardiovascular segment with the launch of 'zocor' (simvastatin) and is planning to tap the potentials in the biologicals in the coming years with the target of emerging as one of the top five players in the country by 2015.
The details can be read here.
No comments:
Post a Comment